Racura Oncology (ASX:RAC)
ASX announcement history & article coverage
Transparent by design.
Announcments by Racura Oncology (ASX:RAC) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
HARNESS-1 First Cohort Cleared
Racura clears RC220 dose escalation to 100 mg/m2 in HARNESS-1 trial
Racura Presents CPACS Data at GCOS 2026
Date of AGM & Closing Date for Director Nominations
Appendix 3Y - Dr Daniel Tillett
Appendix 3Y - Dr Daniel Tillett
RC220 MYC-silencing data to be presented FCS 26 conference
Racura Oncology Adelaide Investor Briefing
Notification regarding unquoted securities - RAC
CPACS Trial Opens for RC220 Patient Enrolment in Korea
Racura Oncology Opens Korean Sites for CPACS Trial Patient Enrolment
Corporate Governance Statement
Appendix 4G
Appendix 4E & Annual Report
Racura Oncology reports $11.1M loss, advances MYC-targeting cancer drug with strong funding
Racure Oncology Techknow Invest Presentation
First HARNESS-1 Patient Safely Treated with RC220
Racura Oncology's HARNESS-1 trial progresses with SRC review and additional patient dosing after Grade 2 colitis reported
June 2026 Quarterly Activities Report and Appendix 4C
Racura Oncology advances clinical trials and secures $34.3M cash runway into 2028
